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Abstract: Several theories on the etiology and pathophysiology of achalasia have been reported 
but, to date, it is widely accepted that loss of peristalsis and absence of swallow-induced 
relaxation of the lower esophageal sphincter are the main functional abnormalities. Treatment 
of achalasia often aims to alleviate the symptoms of achalasia and not to correct the underly-
ing disorder. Medical therapy has poor efficacy, so patients who are good surgical candidates 
should be offered either laparoscopic myotomy or pneumatic balloon dilatation. Their own 
preference should be included in the decision-making process, and treatment should meet the 
local expertise with these procedures. Laparoscopic surgical esophagomyotomy is a safe and 
effective modality. It can be considered as initial management or as secondary treatment if the 
patient does not respond to less invasive modalities. Pneumatic dilatation has proven to be a 
safe, effective, and durable modality of treatment when performed by experienced individuals, 
and appears to be the most cost-effective alternative. For patients with multiple comorbidities 
and for elderly patients, who are not good surgical candidates, endoscopic injection of botulinum 
toxin should be considered a safe and effective procedure. However, its positive effect dimin-
ishes over time, and the need for multiple repeated sessions must be taken into consideration. 
In the management of patients with achalasia, nutritional aspects play an important role. When 
lifestyle changes are insufficient, it is necessary to proceed to percutaneous gastrostomy under 
radiological guidance. In the future, intraluminal myotomy or endoscopic mucosectomy will 
possibly be an option. Further studies are needed to investigate the role of immunosuppressive 
therapies in those cases in which an autoimmune etiology is suspected.
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Introduction
Achalasia is a rare motor disorder of the esophagus and lower esophageal sphincter. 
More specifically, it a neuromuscular disorder characterized by degenerative changes of 
the myenteric plexus leading to a selective loss of inhibitory nerve endings. Irreversible 
disruption of peristaltic contractions and impaired relaxation of the lower esophageal 
sphincter in response to deglutition are the consequences of this damage.1
Primary idiopathic achalasia is a quite rare disease, with an incidence of approxi-
mately 1/100,000/year and a prevalence rate of 10/100,000. Primary achalasia in 
children is part of the Allgrove’s and Alport’s syndromes, and is more frequent in 
Down’s syndrome.2
Secondary achalasia shares clinical features with primary achalasia, but there is 
always an identifiable cause. Worldwide, the most common cause of   secondary   achalasia 
is protozoal infection by Trypanosoma cruzi, found in Central and South America. Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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An association with Class II human   leukocyte antigens3,4 
and some viral infections5 has been described. An autoim-
mune pathogenesis in achalasia has been sustained due to the 
description of antimyenteric neuron antibodies in a subset 
of patients.6
When achalasia is caused by infiltration of the lower 
esophageal sphincter, by malignancy, or by diseases such 
as amyloidosis, or as a result of a paraneoplastic syndrome, 
the term pseudoachalasia is used. Malignancies lead to 
pseudoachalasia most commonly by direct invasion into 
the esophagus and lower esophageal sphincter (most com-
monly gastroesophageal adenocarcinoma, but also oat cell 
carcinoma, bronchogenic carcinoma, esophageal squamous 
cell carcinoma, or lymphoma) or by a paraneoplastic 
phenomenon without cancerous involvement of the lower 
esophageal sphincter.
An achalasic picture may be mimicked by complica-
tions of surgery involving the gastroesophageal junction 
that may lead to impaired passage of esophageal   contents 
into the   stomach, and esophageal dilatation, such as 
  fundoplication, gastric banding, and as a result of injury to 
the vagus nerve.7
From the clinical point of view, achalasia is a progres-
sive disease that presents with symptoms of dysphagia both 
for liquid and solid foods, chest pain and regurgitation of 
undigested foods that occurs during meals, shortly thereafter 
or hours later when the patient changes into the recumbent 
position. More subtle symptoms include slowing of the speed 
of eating and stretching or side-to side movement, as well 
as walking around after meals to accomplish bolus passage 
through the nonperistaltic esophagus and across the hyper-
tonic lower esophageal sphincter. Aspiration of food from 
the esophagus may lead to pneumonia. Loss of weight and 
malnutrition are uncommon, but they may occur in advanced 
disease and in elderly patients.
All patients with dysphagia should undergo upper gas-
trointestinal endoscopy and radiology to rule out anatomic 
lesions as the first diagnostic step.8 Diagnostic accuracy is 
provided only by esophageal manometric studies in over 96% 
of cases showing a typical pattern both in primary achalasia 
and pseudoachalasia.9
The treatment of achalasia has traditionally relied on a 
surgical approach. The advent of minimally invasive sur-
gery with a shorter hospital stay, reduced morbidity, and 
faster return to daily activity, makes this option even more 
  attractive. In contrast, there is evidence that some medical and 
nonsurgical strategies may be of benefit in many patients with 
this disorder. This review summarizes the current knowledge 
and future perspectives for the management of achalasia.
Pathophysiology
Although a full description of the complex and still 
poorly understood mechanisms that underlie achalasia 
are not the aim of this review, a brief summary of these 
is useful in order to comprehend the rationale of different 
treatment options.
The hallmark of achalasia is failure of complete lower 
esophageal sphincter relaxation. The mechanism of lower 
esophageal sphincter relaxation is complex, requiring the 
coordinated interaction of nerves, smooth muscle, inter-
stitial cells of Cajal (ICC), and hormones. Coordinated 
peristaltic waves that move the food bolus through the distal 
esophagus depend on excitatory and inhibitory input from 
local enteric reflexes that originate in the enteric nervous 
plexus and from extrinsic parasympathetic nerves. The 
peristaltic reflex involves both cholinergic and peptide 
excitatory neurotransmission, resulting in contraction of 
both circular and longitudinal muscle proximal to the bolus, 
preceded by aboral relaxation ahead of the bolus. While 
acetylcholine mediates the majority of the neurotransmis-
sion between the vagus and intrinsic neurons, it appears 
that more than one neurotransmitter plays a role between 
the inhibitory myenteric neuron, ICC, and smooth muscle. 
A variety of mediators have been proposed, but the main 
inhibitory factor is nitric oxide.10,11 Thus, the nitric oxide-
releasing inhibitory neurons are the target in idiopathic 
achalasia. The triggering event that leads to ganglion cell 
degeneration in achalasia is still unclear, but loss of nitric 
oxide-secreting neurons leads to an imbalance between 
the excitatory and inhibitory neurons of the myenteric 
plexus, producing irreversible manometric changes in such 
patients.12,13
Intramuscular ICC have been clearly identified in the 
lower esophageal sphincter.14 ICC in the gastrointestinal tract 
have several different functions, serving as pacemakers, as 
generators of a smooth muscle hyperpolarizing factor,15 as 
mechanic sensors,16 and as mediators of neurotransmission.17 
Together with the loss of myenteric neurons, a reduction in 
the number of ICC in the lower esophageal sphincter region 
has also been reported in idiopathic achalasia.18,19 While ICC 
have an established role in mediating nitrogen and cholinergic 
neurotransmission in other regions of the gastrointestinal 
tract, defining the role of ICC in normal lower esophageal 
sphincter function will require further work.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Treatment options
Treatment of achalasia focuses on relaxation or mechanical 
disruption of the lower esophageal sphincter. Achalasia is 
a fairly rare disease, so there are few randomized and con-
trolled clinical trials to define the optimal strategy to treat it. 
Safety, effectiveness, and durability of current treatment 
options vary widely.
The progression of achalasia is due primarily to the 
resistance to the passage of bolus through the poorly relax-
ing and opening lower esophageal sphincter. If achalasia is 
left untreated, a dilated esophagus with severe bolus transit 
impairment will develop, and that condition signals high risk 
for aspiration pneumonia or perforation. Therefore, the goal 
in the management of achalasia is an early diagnosis and 
treatment before reaching this end-stage phase, when sur-
gery becomes mandatory, but usually with a poor outcome. 
An overview of the current therapeutic options in achalasia 
is summarized in Table 1.
Pharmacologic therapy
Pharmacologic therapy for the treatment of achalasia would 
be preferable to the more invasive options for treatment. 
Unfortunately, such treatment does not eliminate the under-
lying disease process, but only temporarily leads to lower 
esophageal sphincter relaxation and may improve   symptoms. 
Nowadays, medical therapy includes nitrates, calcium chan-
nel blockers, and nitric oxide donors in an attempt to either 
facilitate lower esophageal sphincter relaxation and/or 
enhance esophageal peristalsis.
Calcium channel blockers and nitrates, usually taken 
30–60 minutes before meals, have traditionally been the 
focus of pharmacologic therapy. Calcium channel blockers 
inhibit cellular uptake of calcium, and because intracellular 
calcium is necessary for lower esophageal sphincter contrac-
tion, relaxation occurs. Calcium channel blockers have been 
evaluated in the long-term treatment of achalasia, but the use 
of these drugs often induces tolerance, which severely dimin-
ishes the effects over the time. Nifedipine has been shown to 
induce long-term remission and even normalization of physi-
ology in a minority of patients. Verapamil has been shown 
to decrease lower esophageal sphincter pressure, but did not 
demonstrate a relevant symptomatic improvement.20–23
Nitrate therapy acts by counteracting the decrease in 
the inhibitory neurotransmitter, nitric oxide. This leads to 
a decrease in lower esophageal sphincter tone, with a sub-
sequent decrease in lower esophageal sphincter pressure. 
Sublingual isosorbide dinitrate has been shown to decrease 
the basal lower esophageal sphincter pressure and to improve 
esophageal emptying.24 A recent meta-analysis regarding the 
use of nitrates in the treatment of achalasia have found too 
low a number of controlled studies, with heterogeneous data, 
and considerable reported side effects, so was unable to rec-
ommend clinical use of these drugs for the disease.25 Because 
side effects are more profound with nitrates, calcium channel 
Table 1 Current therapeutic options for achalasia
Therapeutic modality Mode of action Adverse effects
Pharmacologic therapy
  Nitrates (isosorbide)
    Calcium channel blockers (nifedipine, 
verapamil)
  5-phosphodiesterase inhibitors (sildenafil)
inhibition of muscle contraction,  
induction of relaxation, promotes  
esophageal emptying
induction of NO release, reduction  
of LES pressure
Hypotension, headache, drowsiness
Hypertension, angina
Endoscopic therapies
    Botulinum toxin (injection into  
the muscular layer of LES)
  Pneumatic dilation of the hypertonic LES
Potent inhibition of the release of acetylcholine,  
improves passive esophageal emptying
Aims at fracturing the fibers of the  
muscularis propria
Feasible and safe on an outpatient basis; 
Heller myotomy could be more difficult in 
patients that underwent repeated injections
Esophageal perforation or rupture, bleeding,  
local pain
Gastroesophageal reflux
Surgery
    Laparoscopic Heller myotomy  
plus antireflux fundoplication
    Esophagogastrectomy with gastric  
or colonic interposition
Deep disruption of muscular hypertonic  
fibers in the LES
Total modification of the LES anatomy;  
to be left for end-stage illness
Although the most “pathophysiologic” 
solution, is costly; possible postoperative 
complications
Gastroesophageal chronic reflux and Barrett’s
very invasive, possible severe complications
Abbreviations: LES, lower esophageal sphincter; NO, nitric oxide.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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blockers are still more widely used. Table 2 summarizes the 
data and the results of chronic prospective and controlled 
studies involving the use of calcium channel blockers and 
nitrates in achalasia.
Sildenafil, a 5-phosphodiesterase inhibitor that reduces 
the breakdown of cyclic GMP, the second messenger medi-
ating nitric oxide-induced relaxation, has been proposed 
as an alternative pharmacologic agent for the treatment 
of   achalasia. Experimental data demonstrate its ability 
to decrease lower esophageal sphincter tone and residual 
  pressure.26 Further studies are needed to determine whether 
this might be of clinical utility in achalasia.
Although a clinical guideline for the management of 
achalasia is still not available, we can assume that pharma-
cologic therapies presently have very limited value in its 
treatment. However, the use of sublingual nifedipine before 
meals seems to remain solely indicated for patients not will-
ing or unable to undergo any other procedure and/or waiting 
for a more definitive therapy, or as supportive treatment for 
refractory chest pain.
Endoscopic therapies
To date, the primary modality of endoscopic therapy for 
achalasia is the injection of botulinum toxin A into the lower 
esophageal sphincter. Botulinum toxin A is a potent inhibi-
tor of the release of acetylcholine, which has an excitatory 
influence on lower esophageal sphincter tone. Injection 
of botulinum toxin A into the lower esophageal sphincter 
improves “passive” esophageal emptying by counterbalanc-
ing the selective loss of inhibitory neurons in the myenteric 
plexus, decreasing lower esophageal sphincter pressure, 
and increasing lower esophageal sphincter opening when 
compared with injection of placebo.27,28
The mean duration of effect of a single injection of 
botulinum toxin A is 10–12 months, with a wide variability 
ranging from three months to three years. The reason for such 
variability is unknown, but is probably related to another 
drawback of the toxin, ie, the development of an   autoimmune 
response with the production of antibodies that may, in turn, 
decrease its efficacy in some patients.
Botulinum toxin A 80–100 U is injected through a 5 mm 
needle into the lower esophageal sphincter, with aliquots 
of 20–25 U of the toxin injected into the four quadrants of 
the lower esophageal sphincter. The procedure is no more 
demanding than a routine endoscopy, and apart from occa-
sional complaints of transient chest pain, patients tolerate 
it very well. They can go home after they recover from 
sedation and are allowed to eat soft foods later in the day. 
Symptomatic improvement occurs gradually and usually 
peaks 1–3 days later, although this may be delayed even 
further in the occasional patient.
Following a single treatment with botulinum toxin A, 
relief of symptoms has been reported in almost 80% of 
patients. After six months, 50% of patients may remain 
in remission, while others will need repeated injections, 
or other treatment options, such as pneumatic dilation or 
surgical myotomy.
Annese28 reported a success rate of 68% at 24 months 
after repeated administration of botulinum toxin A   injection, 
while Pasricha29 found a 30% efficacy rate after a mean 
follow-up of two years. Injection of botulinum toxin A 
seems to be simple and safe, without carrying any risk of 
perforation.30 Post-treatment evaluations have revealed that 
neither pretreatment lower esophageal sphincter pressure, 
amplitude of esophageal contractions, nor duration of illness 
could be used to predict the outcome of botulinum toxin A 
injection. Instead, young age and male gender were found to 
affect the outcome adversely.
Surgeons have reported that Heller myotomy could be 
more difficult in patients who undergo repeated botulinum 
toxin A injection, due to increased adhesion of the muscular 
layer, but, so far, this therapeutic option has to be chosen as 
a first step in all patients who are eligible for it.31 In contrast, 
botulinum toxin A is widely demonstrated to be the most 
Table 2 Clinical studies with calcium channel blockers and nitrates in achalasia
Author Drug Patients (n) Efficacy (%) Follow-up (months)
Gelfonc 1981 isosorbide 24 79 2–19 
Silverstein 1982 Diltiazem 8 50 6
Gelfonc 1982 Nifedipine 15 53 8–18
Bortolotti et al19 Nifedipine  20 90 6–18
Traube 1992 Nifedipine 14 65–80 6
Coccia 1992 Nifedipine 14 77 21
Triadafilopoulos et al20  Nifedipine 14 NA 10
Triadafilopoulos et al20 verapamil 14 NA 10
Abbreviation: NA, not available.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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effective treatment option in elderly patients or in patients 
with comorbid illnesses, in whom dilatation or surgery is 
high-risk.32 Symptom relief was found to last up to 1–2 years 
with a single injection in the elderly.
Historically, pneumatic dilation was the first attempt at 
therapy in esophageal achalasia, and was described in 1674 
by Sir Thomas Willis.32 Pneumatic dilation of the lower 
esophageal sphincter in patients with achalasia aims at 
fracturing the fibers of the muscularis propria. Bougienage 
or a “standard” balloon for dilation are typically ineffective, 
but pneumatic dilation with a rigid and high-sized balloon 
across the lower esophageal sphincter has been shown to be 
effective and quite inexpensive. Forceful dilatation of the 
lower esophageal sphincter is considered to date the most 
effective nonsurgical treatment for achalasia, although details 
of the procedure vary in different institutions. While there 
is no clear consensus on the technical details of balloon 
dilatation, most leading operators used their own pneumatic 
dilatation technique passed along from experienced to junior 
physicians. Inpatient versus ambulatory treatment, sedated 
versus nonsedated dilation, the sedative used, the dilator 
system, initial balloon size, speed, pressure, duration, number 
of dilations per endoscopic session, and timing of redilations 
differ from center to center.34–37
Typically, pneumatic dilation is performed over a guide 
wire under fluoroscopic guidance. This allows for assess-
ment of the progress of dilation as the narrowed “waist” 
of the lower esophageal sphincter disappears. However, 
in addition to radiation exposure, this requires bulky and 
expensive fluoroscopy equipment, which may be in high 
demand or not available for general use. Performing pneu-
matic dilation under direct endoscopic visualization is a good 
alternative to fluoroscopic guidance. After placement of the 
dilator over the guide wire, the endoscope is reinserted into 
the esophagus. The balloon placement and dilation effects 
are observed proximal to the balloon. This method has been 
performed for more than 20 years,38 and the American Society 
of   Gastrointestinal Endoscopy has suggested that either visu-
alization method is acceptable for safe dilation in achalasia.39 
Major complications are rare after pneumatic dilation. The 
most serious complication is esophageal perforation, which 
occurs at a mean rate of about 2.5%.40 Gastroesophageal 
reflux is the most frequent chronic complication after lower 
esophageal sphincter dilation for achalasia. With 24-hour pH 
monitoring and esophageal manometry, it is possible to define 
the pathophysiologic subset of the reflux, because it is nearly 
always associated with a hypotensive lower esophageal 
sphincter and ineffective esophageal body motility.41
Some investigators debate the role of botulinum toxin A 
injection versus pneumatic dilation. A recent Cochrane review 
of six randomized controlled trials including 178 patients 
evaluated symptom recurrence after esophageal dilation 
versus endoscopic botulinum toxin A injection at one, six, 
and 12 months after treatment. Thirty percent of patients 
undergoing dilation experienced symptom recurrence and 
treatment failure at 12 months versus 74% of patients who 
received botulinum toxin A.42 Furthermore, a systematic 
review and meta-analysis of 105 papers that reported on 
761 patients with achalasia who underwent endoscopic treat-
ment with esophageal dilation or botulinum toxin A showed 
that symptom relief was better for dilation, and the necessity 
for further treatment was significantly reduced.43
Surgery
Minimally invasive surgical techniques have dramatically 
modified the management algorithm of the treatment of 
achalasia. The advantage of a less invasive, safe, and effec-
tive surgical option prompts gastroenterologists to choose 
patients earlier for surgery, because this obviates the need 
for dilation.44,45
Currently, the standard surgical management for acha-
lasia is the laparoscopic Heller myotomy, first reported in 
1991.46 This technique is associated with the greater decrease 
in dysphagia, a shorter hospital stay, lower risk of postopera-
tive gastroesophageal reflux, and low complication rates.47 
An antireflux procedure can further reduce postoperative 
heartburn rates by 80%, as well as the risk of esophagitis 
and peptic stricture. A Dor or Toupet fundoplication reduces 
reflux as well as a Nissen procedure, but the partial wraps 
trend toward less dysphagia. The dysphagia rate attributed to 
fundoplication ranges from 0% to 8%. Failure of improve-
ment with dilatation suggests incomplete myotomy and a 
requirement for repeat manometry. Optimal length of the 
cardiomyotomy is at least 2 cm. Although a Dor fundoplica-
tion is more commonly reported, the choice of Toupet versus 
Dor depends on surgeon preference.48 There are very few 
randomized prospective trials examining esophagomyotomy 
versus pneumatic dilation.49 One study showed equivalent 
effectiveness at relieving symptoms initially, but at follow-up 
it showed those patients who had esophagomyotomy had 
fewer recurrent symptoms than those who had pneumatic 
dilation. Very recent preliminary data from a large and 
powerful multicenter randomized clinical trial comparing 
the treatment success of these two different therapies sug-
gest that, after two years of follow-up, pneumatic dilation 
and laparoscopic myotomy have a comparable success rate Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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of 87%–92%.50 Some studies suggest that pneumatic dilation 
may achieve long-term relief of symptoms in patients older 
than 50 years.51
Despite symptom improvement by either pneumatic dila-
tion or surgical myotomy in achalasia patients, 10%–15% of 
those so treated will present with progressive deterioration 
in their esophageal function, and up to 5% may eventually 
require an esophagectomy. The optimal reconstruction 
for the resected esophagus should be gastric interposition, 
colon interposition, and jejunal interposition, all of which 
have their respective advantages and disadvantages.52,53 It is 
questionable if progression to esophageal cancer following 
Heller myotomy (adenocarcinoma in Barrett’s esophagus or 
squamous cell carcinoma) is a failure of surgery or a failure of 
follow-up. Development of adenocarcinoma after myotomy 
in the sequelae of Barrett’s esophagus might be due to a too 
long myotomy, and only few case reports on this association 
are available.54
Nutritional approach
The management of the patient with achalasia and nutritional 
problems is very similar to that of patients with dysphagia 
due to neurologic disease or esophagogastric cancer.55,56 Oral 
feeding has relevant psychosocial significance to patients 
and their families, and should be continued whenever pos-
sible. In some patients, oral intake is often not adequate 
even in the absence of significant swallowing difficulties. 
In mild to moderate achalasia, nutrition is generally mildly 
affected and, if the family encourages the patient to follow 
dietary modifications, loss of weight and malnutrition rarely 
occurs.
Dysphagia diets should be highly individualized, includ-
ing modification of food texture or fluid viscosity. Food 
may be chopped, minced, or puréed, and fluids may be 
thickened.57
If a patient is unable to eat or drink or to consume suffi-
cient quantities of food, or the risk of pulmonary aspiration is 
high, tube feeding should be provided. If there is a possibility 
for surgical myotomy, enteral nutrition via a nasal feeding 
tube will be adequate as a provisional measure, consider-
ing that a malnourished patient is always at major risk for 
postoperative complications. In very rare and selected cases 
of end-stage achalasia, in which there is any further possi-
bility of surgery or pneumatic dilation, the insertion of the 
feeding tube through a percutaneous radiologic gastrostomy 
rather than a surgical gastrostomy would be the treatment 
of choice. Percutaneous gastric tube feeding is effective and 
usually acceptable to patients and their carers. Long-term 
complications include tube obstruction and wound infection. 
In some patients who are fed via a gastric tube, pulmonary 
aspiration may occur and routine intrajejunal feeding has 
been suggested for these cases.58
Possible future therapies
The utility of self-expanding 30 mm endoscopic metallic 
stents for achalasia has been prospectively evaluated in 
75 patients at a single center over a 13-year period. The 
clinical success rate after 10 years of follow-up after the 
stent was removed was high (83%). There were no perfora-
tions or mortality associated with the treatment, but stent 
migration occurred in 5% of patients, reflux in 20%, and 
chest pain in 38.7%.59
Pasricha reported a method of submucosal endoscopic 
myotomy with no skin incision in an experimental   model.59 
More recently, Inoue described a clinical application of 
modified Pasricha technique as per oral endoscopic myotomy 
(POEM) to provide a less invasive permanent treatment for 
esophageal achalasia.60 Thirty-five achalasia patients who 
had lasting symptoms of dysphagia received POEM.61 Bar-
ium swallows before and after the procedure demonstrated 
total release of thickened lower esophageal sphincter. Mean 
operating time was about 120 minutes and the mean hospital 
stay after the procedure was 4.9 days. No severe complica-
tion was reported and dysphagia symptoms disappeared after 
the procedure. Mean resting pressure of the sphincter fell. 
Subjective symptom score was significantly improved in all 
cases. This method is achieved with the already available 
techniques and devices for routine endoscopic myotomy. 
This procedure allows a direct approach to the thickened 
inner muscular layer with no skin incision and effectively 
releases lower esophageal sphincter pressure. Myotomy 
length can be flexibly determined according to the patients’ 
symptoms, such as dysphagia and chest pain. This seems 
to be a very promising technique possibly leading to a new 
frontier for endotherapy of achalasia, but further studies 
of the long-term efficacy and a comparison of POEM with 
other interventional therapies are awaited.62
In view of the fact that the enteric neurons innervating the 
esophagus and the lower esophageal sphincter could disap-
pear due to an autoimmune mechanism, immunosuppressive 
therapy could prevent disease progression.63 However, at 
the time of diagnosis, the number of neurons has already 
decreased, leading to significant dysfunction and symptoms. 
Although this approach may theoretically prevent further 
disappearance of neurons, it is possible that comes too late 
and will fail to restore function.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Recent experimental studies in mice suggest that trans-
plantation of neuronal stem cells might be a future therapeutic 
option. Indeed, neuronal stem cells injected in the pylorus 
survived and even expressed nitric oxide synthase.64 The 
advantage of such a technique would be that not only would 
sphincter function be restored, but perhaps even peristal-
sis too. That is a very suggestive hypothesis, and clearly 
a lot of research remains to be done further exploring this 
approach.
Decision-making  
and cost-effectiveness
The appropriate treatment for any given patient with 
achalasia depends on their willingness to undergo invasive 
procedures and on their physical ability to endure them. 
A decision   analysis model has been developed for the treat-
ment of achalasia. Four therapeutic options were evaluated, 
ie,   laparoscopic Heller myotomy and partial fundoplica-
tion, pneumatic dilation, botulinum toxin injection, and 
thoracoscopic Heller myotomy. Based on complications, 
need for repeated procedures, and overall treatment cost, 
it has been found that laparoscopic Heller myotomy with 
fundoplication was the preferred treatment strategy.65 
The authors recommended that those patients who meet 
diagnostic criteria for achalasia (manometric, endoscopic, 
radiographic) in a referral center and who are good surgical 
candidates should be referred to an experienced surgeon 
for minimally invasive modified Heller myotomy. Patients 
who are not good surgical candidates and cannot accept the 
risk of pneumatic dilation can be treated with single-shot 
or repeated botulinum toxin A injection or can be treated 
with pharmacological agents.
Several cost analyses have been performed to verify 
which modality of treatment is the most cost-effective. 
Multiple studies evaluating the cost of the initial 5–10 years 
of therapy have demonstrated that pneumatic dilatation 
is the most cost-effective modality in otherwise healthy 
  populations.66 In patients with other comorbidities that 
decrease life   expectancy, botulinum toxin A is more 
  cost-effective.67 Although surgery seems to be the most 
definitive and effective treatment for achalasia, it appears 
to be costly over the initial years of therapy.
Summary
Although the ultimate goal of the treatment of esophageal 
achalasia should be the restoration of esophageal peristalsis 
and lower esophageal sphincter relaxation, at present there 
is not a known therapeutic option addressing this goal, and 
both gastroenterologists and surgeons continue to destroy 
the lower esophageal sphincter. Whereas medical therapy has 
poor, if any, results, Heller myotomy and pneumatic dilata-
tion are successful in 70%–90% of patients in the first year, 
but the success rate slowly declines with time. Botulinum 
toxin injection in the lower esophageal sphincter is safe and 
effective, but it has to be reserved for elderly patients with 
comorbid illnesses. Pneumatic dilation or Heller myotomy 
seems to be the best solution, each modality having techni-
cal problems and possible complications. Which of these 
treatments might be the therapy of choice for achalasia in 
particular subgroups of patients remains to be investigated. 
Clearly, more research is required to develop therapies to 
restore the functional anatomy of the lower esophageal 
sphincter.
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